<DOC>
	<DOCNO>NCT00555724</DOCNO>
	<brief_summary>Phase 1 , open-labeled , dose escalation safety tolerability study treatment subject relapse refractory solid tumor .</brief_summary>
	<brief_title>Phase 1 Study BIIB022 ( Anti-IGF-1R Monoclonal Antibody ) Relapsed/Refractory Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Age 18 year old time inform consent Relapsed refractory solid tumor follow standard therapy . ECOG Performance Status 0 1 . History insulindependent diabetes , type 2 diabetes , hemoglobin A1c &gt; 6 % screening . History myocardial infarction within 12 month prior Day 1 chronic heart failure . Known central nervous system brain metastasis . Prior antiIGF1R therapy kind . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Relapsed</keyword>
	<keyword>refractory</keyword>
	<keyword>solid tumor</keyword>
</DOC>